Cancer Trials / Trials in Montana
106 Recruiting Trials

Clinical Trials
for Cancer in Montana

106 clinical trials for Cancer are currently recruiting participants at study sites in Montana. Study-related care is provided at no cost.

106
Recruiting trials
57
Study sites
10
Cities
33
Industry-sponsored
34
Phase 2
65
Phase 3

Cancer clinical trials in Montana: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Montana, recruiting cancer studies are concentrated in Billings, Bozeman, Great Falls and Missoula, with sites in 6 other cities. 33 of the 106 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 106 recruiting Cancer trials in Montana

Integrated Cancer Repository for Cancer Research
N/A Greenwood Village, Colorado +4 sites NCT02012699
This trial is looking for adults who have a history of cancer, are at risk for developing cancer, or are healthy individuals. Participants will provide consent and may help advance cancer research by sharing data and samples.
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites NCT06136650
This trial is looking for men with metastatic castration-resistant prostate cancer who have been treated with one hormonal therapy before. Participants will receive either opevesostat with corticosteroids or other alternative treatments to see which is more effective.
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
PHASE3 Bakersfield, California +4 sites NCT06345729
This trial is looking for adults diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has a certain genetic mutation. Participants will receive a combination of two drugs, calderasib and pembrolizumab, to see how well they work together as a first treatment option.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Birmingham, Alabama +4 sites NCT04928846
This trial is looking for adults with a type of lung cancer who have already had treatment. Participants will receive either telisotuzumab vedotin or docetaxel through an IV every couple of weeks to see how well they work and how safe they are.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
PHASE3 Sacramento, California +4 sites NCT07513376
This trial is looking for people with high-risk non-small cell lung cancer that has been surgically removed. Participants will receive either one or two investigational treatments to help prevent the cancer from coming back after surgery.
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
PHASE3 Phoenix, Arizona +4 sites NCT06925737
This trial is looking for men with advanced prostate cancer that has spread. By participating, I may receive a treatment called ifinatamab deruxtecan and help researchers learn if it works better than standard chemotherapy.
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
PHASE3 Anchorage, Alaska +4 sites NCT07214779
This trial is looking for women with a specific type of ovarian cancer that hasn't responded to platinum-based treatments. Participants will receive the drug INCB123667 or a chemotherapy chosen by their doctor.
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3 Jonesboro, Arkansas +4 sites NCT06757634
This trial is looking for adults with advanced breast cancer that is HR-positive and HER2-negative. Participants will receive treatment involving gedatolisib along with other medications.
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
PHASE3 Mobile, Alabama +4 sites NCT07228832
This trial is looking for patients with metastatic colorectal cancer who have not received any previous treatment. Participants will receive either Ivonescimab or Bevacizumab combined with chemotherapy as their first treatment.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
PHASE3 Billings, Montana +4 sites NCT07851025
This trial is looking for women with advanced epithelial ovarian cancer who have already received some treatments. Participants will receive a new combination therapy after their initial chemotherapy.
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
PHASE3 Fullerton, California +4 sites NCT06758401
This trial is looking for people with advanced lung cancer who have high levels of a specific protein called PD-L1. Participants will receive a combination treatment of two medications or just one and will be monitored regularly at a clinic.
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
PHASE3 Mobile, Alabama +4 sites NCT06561386
This trial is looking for people with advanced non-small cell lung cancer who have not received prior treatment. Participants will compare two different groups of treatment involving chemotherapy and specific medications.
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
PHASE3 Tucson, Arizona +4 sites NCT07409272
This trial is looking for people with pancreatic cancer that has spread and a specific gene mutation. Participants will receive a medication called setidegrasib along with standard chemotherapy to see if it helps improve their treatment outcomes.
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06899126
This trial is looking for adults with advanced lung cancer that has specific characteristics. Those who qualify will receive a combination of treatments to see how well they work.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
See all 106 Cancer trials in Montana

Where the Cancer studies are in Montana

Research sites running the most studies
  • Billings Clinic Cancer Center, Billings68 trials
  • Bozeman Health Deaconess Hospital, Bozeman60 trials
  • Benefis Sletten Cancer Institute, Great Falls59 trials
  • Community Medical Center, Missoula59 trials
  • Community Hospital of Anaconda, Anaconda52 trials
  • Logan Health Medical Center, Kalispell51 trials
By city

Counts are recruiting studies listing at least one site in Montana, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Montana: common questions

How many Cancer clinical trials are recruiting in Montana?
TrialFinder currently lists 106 recruiting Cancer clinical trials with study sites in Montana. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Montana?
Study sites for the Cancer trials listed on this page include Billings. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Montana?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Montana also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Montana?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Cancer Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Montana.

Get Matched — Free
No insurance required
About Cancer Trials

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →
Other Conditions in Montana
Diabetes Breast Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in Montana →